Product
MT-5111
1 clinical trial
1 indication
Indication
HER2-positive Solid CancersClinical trial
A Phase 1 Open-label, Multicenter Dose Escalation and Expansion Study of MT-5111 in Subjects With Previously Treated Advanced HER2-positive Solid TumorsStatus: Terminated, Estimated PCD: 2023-02-01